Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Simon Parkinson

Nurse Practitioner, Family Chandler, AZ Nurse Practitioner

NPI 1114990371 CMS profile 11097421

4045 W Chandler Blvd Bldg F, Chandler, AZ 85226

Open in the dashboard

General payments

$40,229

880 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Simon Parkinson of Chandler, AZ is reported in the CMS Open Payments database as having received $40,229 across 880 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,848 168
2024 General $9,138 186
2023 General $7,500 228
2022 General $4,952 121
2021 General $8,791 177

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Simon Parkinson
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Simon Parkinson were reported at $9,848. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Simon Parkinson Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $8,791 $124 $35–$379 $132
2022 $4,952 $141 $44–$430 $149
2023 $7,500 $154 $49–$476 $160
2024 $9,138 $165 $51–$504 $164
2025 $9,848 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $22,587 243 payments
  2. Ipsen Innovation $3,886 9 payments
  3. Allergan Inc. $1,041 22 payments
  4. Biogen, Inc. $1,020 51 payments
  5. Pfizer Inc. $972 55 payments
  6. Jazz Pharmaceuticals Inc. $832 24 payments
  7. Novartis Pharmaceuticals Corporation $731 45 payments
  8. UCB, Inc. $657 33 payments
  9. CSL Behring $618 25 payments
  10. Teva Pharmaceuticals USA, Inc. $474 28 payments
  11. Other $7,412 345 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $19,976 19 payments
  2. Food and Beverage $16,562 837 payments
  3. Travel and Lodging $3,199 6 payments
  4. Education $492 18 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $19,921 140 payments
  2. QULIPTA $6,481 105 payments
  3. NURTEC ODT $882 54 payments
  4. ZAVZPRET $802 49 payments
  5. Hizentra $618 25 payments
  6. TYSABRI $582 21 payments
  7. XYWAV $553 17 payments
  8. VUMERITY $478 25 payments
  9. DUOPA $459 29 payments
  10. KESIMPTA $454 24 payments
  11. Other $10,974 561 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 85 drugs

Part D claims

5,449

Median for Nurse Practitioner: 389

Drug cost

$1,081,455

Median for Nurse Practitioner: $21,885

Branded share of claims

24.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gammaked Immune Globul G/Gly/Iga Avg 46 Brand 28 $287,613
Botox Onabotulinumtoxina Brand 87 $111,009
Kesimpta Pen Ofatumumab Brand 11 $94,658
Aimovig Autoinjector Erenumab-Aooe Brand 109 $90,449
Emgality Pen Galcanezumab-Gnlm Brand 114 $80,295
Nurtec Odt Rimegepant Sulfate Brand 46 $72,578
Qulipta Atogepant Brand 64 $72,225
Ubrelvy Ubrogepant Brand 44 $52,088
Aptiom Eslicarbazepine Acetate Brand 26 $32,723
Rytary Carbidopa/Levodopa Brand 26 $24,941

The 10 drugs with the highest cost, of 85 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$71,003

Of which drugs: $670

Medicare patients

395

Average age 73

Services billed

2,806

255 women, 140 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Diabetes 35%
Depression 31%
Chronic kidney disease 30%
Ischemic heart disease 26%
Osteoporosis 21%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, mepivacaine hydrochloride, per 10 ml J0670 Office 35 113 $261
Injection, thiamine hcl, 100 mg J3411 Office 24 85 $149
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 27 89 $95
Injection, ketorolac tromethamine, per 15 mg J1885 Office 37 192 $92
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 35 60 $41
Injection, promethazine hcl, up to 50 mg J2550 Office 11 14 $22

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 44 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
$2,993 44 —
QULIPTA
$1,647 64 —
ZAVZPRET
$235 — —
ZEPOSIA
$188 — —
Leqembi
$177 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 44 with Patron

Records

880 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record